Michael Howell Buys 7,987 Shares of Zura Bio Limited (NASDAQ:ZURA) Stock

Zura Bio Limited (NASDAQ:ZURA) insider Michael Howell bought 7,987 shares of Zura Bio stock in a transaction dated Monday, April 22nd. The stock was purchased at an average cost of $3.13 per share, for a total transaction of $24,999.31. Following the completion of the acquisition, the insider now directly owns 7,987 shares of the company’s stock, valued at approximately $24,999.31. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Zura Bio Price Performance

Shares of NASDAQ:ZURA opened at $3.62 on Friday. Zura Bio Limited has a 52 week low of $2.00 and a 52 week high of $14.00. The firm has a 50 day moving average of $3.19 and a 200 day moving average of $4.03.

Analyst Ratings Changes

Separately, Oppenheimer reiterated an “outperform” rating and issued a $16.00 price target (down previously from $17.00) on shares of Zura Bio in a research report on Monday, April 1st. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $16.40.

Hedge Funds Weigh In On Zura Bio

A number of large investors have recently bought and sold shares of the business. Forefront Analytics LLC raised its stake in Zura Bio by 46.8% in the fourth quarter. Forefront Analytics LLC now owns 21,229 shares of the company’s stock worth $99,000 after buying an additional 6,765 shares in the last quarter. Raymond James & Associates increased its position in shares of Zura Bio by 14.0% during the third quarter. Raymond James & Associates now owns 77,356 shares of the company’s stock worth $511,000 after purchasing an additional 9,481 shares in the last quarter. Lynx1 Capital Management LP acquired a new position in shares of Zura Bio during the third quarter worth $65,000. Bank of New York Mellon Corp acquired a new position in shares of Zura Bio during the third quarter worth $224,000. Finally, Eisler Capital US LLC acquired a new position in shares of Zura Bio during the third quarter worth $660,000. Institutional investors own 61.14% of the company’s stock.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.